Opioid Toxicity in the Setting of Acute Kidney Injury

This is opioid-induced neurotoxicity until proven otherwise, driven by renal failure. Morphine is metabolized to morphine-6-glucuronide and morphine-3-glucuronide, both renally cleared. In acute kidney injury these accumulate; M6G is analgesic and M3G is thought to drive myoclonus, hyperalgesia/allodynia, and agitation. The syndrome is not simply "too much opioid" - she is in pain, which is the trap. Escalating the morphine would worsen the neurotoxicity while leaving pain undertreated.

Why not just progression or dehydration: dehydration and vomiting explain the AKI and probably precipitated it, but they do not explain allodynia and hallucinations in a patient who was previously lucid on a stable dose.

What to check, efficiently:

• Repeat calcium (malignancy-associated hypercalcemia can mimic this - 8.9 mg/dL is reassuring but recheck).
• BUN, electrolytes, magnesium, phosphate, glucose, ammonia only if encephalopathy is prominent.
• Infection screen if febrile or if there is any focal sign.
• Brain imaging if there are focal deficits, headache, or if the picture does not resolve after opioid rotation.

The reasoning point: the diagnosis is made clinically and confirmed by response to rotation. If the myoclonus and agitation improve within 24–48 hours of switching to a renally-safe opioid and correcting the AKI, the diagnosis holds. Delaying the switch in order to "get more data" prolongs a reversible, distressing, and potentially seizure-associated state.

Step 1 - total current oral morphine equivalent.

• Extended-release: 60 mg × 2 = 120 mg/day
• Rescue: 15 mg × 4 = 60 mg/day
• Total = 180 mg oral morphine/day

Step 2 - convert to fentanyl. Using the common approximation that 60 mg of oral morphine per 24 hours ≈ 25 mcg/hr of transdermal fentanyl, 180 mg/day ≈ 75 mcg/hr.

Step 3 - reduce for incomplete cross-tolerance. Because she is opioid-tolerant but rotating to a new agent, reduce by 25–50%: ≈ 37–50 mcg/hr equivalent, or roughly 40 mcg/hr as a starting anchor.

Step 4 - choose the formulation, and this is the real judgment.

• Do not use a transdermal patch here. Absorption is unreliable in a patient with orthostatic hypotension, vomiting, and evolving renal function; the patch also cannot be titrated for days.
• Start an intravenous fentanyl infusion or PCA (for example 25–50 mcg/hr basal with a small demand dose), and stop morphine.
• Fentanyl is the preferred agent in renal failure because it has no renally accumulating active metabolites.

What not to reach for: hydromorphone and oxycodone both have renally cleared metabolites that accumulate; they are better than morphine but not truly safe in this setting. Meperidine is contraindicated.

Adjuncts. Treat the myoclonus with clonazepam 0.5 mg every 8 hours or midazolam if agitation is prominent. Methadone is attractive in principle (NMDA antagonism helps hyperalgesia, no active renal metabolites) but it accumulates and prolongs QT in renal failure and requires expertise - reasonable under palliative care guidance, not as a first reflex.

Reassess at 24 hours for pain score, sedation scale, myoclonus, and respiratory rate, and titrate - the conversion is an estimate, not a prescription.

Medical stabilization:

• Volume resuscitation with isotonic fluid, with attention to urine output; she is orthostatic and dry.
• Correct the AKI precipitant: hold further nephrotoxins, review whether any component of her regimen or supportive medications (NSAIDs for pain, contrast, bisphosphonates) is contributing.
• Antiemetic regimen that is not nephrotoxic; avoid NSAIDs entirely.
• Monitor for the complication that kills people in this scenario: if she becomes oliguric and hyperkalemic or acidotic, escalate early rather than late.

Prognosis conversation - this is the part that is easy to skip. A hospitalization for AKI on active chemotherapy in metastatic pancreatic cancer is a fork in the road, not a minor setback. Before discharge, clarify:

• Whether she wants further chemotherapy after this episode, and what the realistic benefit is.
• Whether her pain regimen should be reframed around comfort, with a plan for home IV or subcutaneous fentanyl if she cannot take oral medications.
• Code status and health care proxy, framed as "what would you want if this happened again and was worse."
• Whether home hospice is the right setting; if she is spending most of the day in bed with ECOG 3, that discussion should be offered, not deferred.

Care coordination. Document the rotation, the new opioid, and the reason (renal failure, morphine metabolite accumulation) in the discharge summary and in the medication list the pharmacy sees. Repeat toxicities after opioid rotation in renal failure are common because the old drug is still on the list.